tradingkey.logo

BUZZ-Hims & Hers slides on warning it may stop compounded version of Wegovy

ReutersFeb 25, 2025 11:20 AM

Shares of telehealth firm Hims & Hers HIMS.N fall 19.22% to $41.45 premarket

Co says may no longer be able to sell compounded versions of Novo Nordisk's NOVOb.CO weight-loss drug Wegovy, after US FDA removes it from shortage list

Adds the move could lead to customers cancelling their subscriptions, affecting revenue

Shares have risen 5 fold in the last 12 months

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI